Compare ResMed Inc. (RMD) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs ProShares Ultra Semiconductors — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while ProShares Ultra Semiconductors trades at $89.09. The key difference: ResMed Inc. pays a 1.19% dividend while ProShares Ultra Semiconductors pays none, and ProShares Ultra Semiconductors is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | USD | |
|---|---|---|
Market Cap | $31.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $283.28 | $113.53 |
52-Week Low | $182.82 | $43.19 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
USD stock trades at $89.70, up 1.01% with bullish technical signals from moving averages. The company announced a dividend of $0.14 per share scheduled for June 2026. Technical indicators show strong support at $88 and resistance at $92, with RSI levels in neutral territory suggesting balanced momentum.
The stock shows technical strength but lacks current fundamental data for comprehensive valuation. The upcoming dividend provides income appeal, though investors face uncertainty without recent financial metrics. Market sentiment appears cautiously optimistic given the technical setup and corporate action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
